Unlocking the Future of Dialysis

 
 

About Advent Access

Advent Access is a medical technology startup focused on end-stage renal disease management. A Stanford StartX company and spin-off from A*STAR, Advent’s mission is to pioneer innovations to significantly reduce dialysis cost and improve quality of life for kidney failure patients. The company’s first product is the av-Guardian™ - an award-winning implant technology that aims to improve vascular access reliability, enable less-painful cannulation and, in the long run, potentially reduce vascular access related hospitalizations. The av-Guardian™ forms a key component of Advent Access’ dialysis-machine agnostic platform to empower patients to perform guided hemodialysis consistently and safely across dialysis care environments. 

 

News

Advent Access today announced receipt of the CE Mark certificate for its award-winning av-Guardian™ vascular access system. The certificate indicates av-Guardian™’s conformity with health, safety, and environmental protection standards set by the European Union for a device to be distributed into the European Economic Area.

          

Read more

Advent Access, an end-stage renal disease management medical technology company who designed and developed the av-Guardian™ Vascular Access System, is proud to share it has received ISO 13485:2016 certification for its Quality Management System from DEKRA Certification B.V. 

ISO 13485 is an internationally recognized standard specific to the medical device industry for a quality management syst...

CEO Ruey Feng PEH spoke with CNBC about our invention, av-GuardianTM, and its potential to transform kidney dialysis care by allowing more patients to be treated while reducing costs. We believe that av-Guardian has the potential to assist patients in self-needling, and we aim to unlock the future of independent dialysis.

  

Link to video >

Please reload

 

Executive Committee

lu yoh-chie
peh ruey feng
abel ang

Clinical Advisors

ken.png

Clinical Advisor

Picture1 copy.png

Patient Engagement Advisor

 

Safety &
Performance Study

Study name  

Non randomised safety and performance evaluation of the av-Guardian Vascular Access System for hemodialysis patients

Study site  

Multi-center Singapore study at Singapore General Hospital, National University Hospital, supported by National Kidney Foundation, Singapore 

Self-Cannulation &
Self-Hemodialysis Study

Study name  
Non randomised safety and performance evaluation of the av-Guardian Vascular Access System for deep AVF & for use of self-cannulating patients.

Study site  
Waikato Hospital, New Zealand

 
 

©2019 By Advent Access Pte. Ltd. All Rights Reserved.